We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.50 | 1.40 | 1.60 | 1.50 | 1.50 | 1.50 | 195,426 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -4.29 | 2.03M |
Date | Subject | Author | Discuss |
---|---|---|---|
28/5/2020 12:31 | He clearly got hooked in at a much higher share price and is not a happy bunny!! | billthebank | |
28/5/2020 12:13 | Spacedust, you had the opportunity to sell at 10p on 29th April but by then you had switched into bull mode..... spacedust 28 Apr '20 - 16:07 - 4875 of 5473 Don't sell at 8.2p h9ld on til 16.5p so you double. I've requested this to finish 10p on close and 100% rise first thing tomorrow You must be confident of 16p then if 10p was not good enough price..... | bones | |
28/5/2020 12:11 | You can always buy below fundraise price when the share price goes below the placing price. Now some smart assesses will say 3.5p is the floor and why would the share price go below the placing price | spacedust | |
28/5/2020 11:51 | Fund raise at 3.5p, Can still buy under 4p. What's not to like. | mam fach | |
28/5/2020 11:24 | Unless JC aka ZA this shttt share with undisclosed fee contracts ain't going nowhere. Cunning must step down | spacedust | |
28/5/2020 09:11 | This will bounce | volsung | |
27/5/2020 20:58 | Yes and it works everytime for the crooks. I just want out of this shttt aim shares. I have three left Pyc Sar And tly but tly are solid producing profits and paying dividends. Over the past couple of yrs I've been coming out of aim shares and invest in ftse 100 and 250 companies and I've done a lot better. So I'm going to stick to that. Next step sell PoooYC and Sar and never invest in aim shares ever again | spacedust | |
27/5/2020 14:40 | He won't stop it and he can't. Stig has a been pumping ramping this shttt share or 3yrs non stop Only hope is jc | spacedust | |
27/5/2020 14:29 | This should apply to all those R&D on twitter, seems only powerful people can stop it hxxps://www.ndtv.com | euclid5 | |
27/5/2020 13:18 | Who needs analysis when they have you fantasising over how much each and every company you invest in is worth. | cocker | |
27/5/2020 13:16 | Cunning jim couldvesuly sell his 3.5p discounted batch at 3.85p and make 10% profit. A lot of pyc contracts are UNDISCLOSED FEE. What a cunning piece of asssswipe cunning thief is. Jim the cunning | spacedust | |
27/5/2020 12:25 | Downward dog sorry folks | chesty1 | |
27/5/2020 10:20 | Added a further 100k at 3.79. Well hidden by a public quote of 3.7-4.1 | bones | |
27/5/2020 10:19 | If this Big Pharma contract is similar to Merck then PYC's revenues will jump to over £1m p.a. Given industry revenue multiples of 15-30x that should imply valuation of £15-30m or 15-30p a share That's for the core Modelling and Simulation business I believe the AI/ML Personalised Medicine (which they refer to as the blue sky growth part) is worth £50m+ | the stigologist | |
27/5/2020 10:15 | One of the problems PYC Physiomics has had getting the respect/valuation it deserves has been the lack of a decent UK quoted comparitor to help analysts and investors gain a better understanding of the market it operates in, the industry dynamics and the appropriate valuation benchmark Although there still remains no viable UK comparitor in recent months an interesting US comparitor has emerged which may help Investors understanding and appreciation of PYC What is interesting is that this is no ordinary comparitor. This Company has been described by Citron Research as a 'Tesla type' industry disruptor, the most important IPO in the last 5 years and has Bill Gates and D.E.Shaw as major cornerstone investors (together owning c.50%). Citron Research are mainly known as a specialist 'Bear' research house often debunking 'hot' stocks so it's interesting that they are so positive on this particular concept stock. The stock in question is SDGR Schrodinger a Company founded in 1990, the current CEO joined in c.2002. It has taken them up now to IPO (February 2020) since when the stock has tripled ! ($17 to $55) and the Company is currently valued at over 30x (yes THIRTY times!) Revenue (2019 revenue $86m ; Mkt Cap $2.7bn) The underlying story of Schrodinger is that of applying computer modelling techniques to drug discovery. Global Pharma/Biotech spends c.$180bn a year on R&D. So SDGR has a potentially huge market still left to penetrate. Faced with a US tech comparitor the usual response from UK cuck analysts/Fund Managers is 'well US equity investors apply higher ratings to US stocks that's just the way it is' However there is very good reason to make the case that Physiomics should not only be valued at 30x revenue but could deserve a premium! SDGR is valued at 30x Revenue because US investors believe it has a wide open growth opportunity to eat into the $180bn Global Pharma R&D market opportunity If US investors are prepared to pay so much for future growth how much would PYC be worth as a 'growth option' acquisition for either SDGR or a peer such as Private Equity roll-up Certara ? - PYC would give SDGR access to computer based modelling and simulation expertise in the Drug Development part of the R&D cycle rather then just Drug Discovery - PYC would give SDGR access to European geography - PYC would give SDGR access to customers SDGR might not otherwise have access to (Merck, Bicycle Therapeutics) Applying a 30x valuation to PYC's trailing 12 month revenues would imply a valuation of £23m (compared to the current £2.9m) a share price of 32.5p versus current 4p NB : That valuation applied to Physiomics 'bread and butter' modelling and simulation business which is analagous to Schrodinger. Physiomics also have a 'blue sky' story in utilising their Virtual Tumour cancer modelling expertise to offer a 'Business to Consumer' Universal Cancer Decision Support System through NHS/Clinicians which could be worth... well name your price. UK unicorns in AI/ML pharma/bio space are valued at Billions on zero revenue. | the stigologist | |
27/5/2020 10:15 | I think it's now 3 massive inflection points for PYC story 1. Getting another Big Pharma contract 2. Getting a proper Institutional Investor on board 3. Getting a highly regarded market comparitor so people understand what you do/industry dynamics better | the stigologist | |
27/5/2020 10:06 | I can’t see how you can go too far wrong at this level. Bought 250k this morning at average 3.85, just 10% above placing price. Seeing how this share can move like manure from the shovel on not a lot (see recent move to 10p), the risk/reward odds look ok to me. | bones | |
27/5/2020 09:31 | Like I said cunning jim | spacedust | |
27/5/2020 09:31 | AVCT Management own less than 1% of the shares in AVCT | the stigologist | |
27/5/2020 09:04 | Yes probably another undisclosed fee contract. Stupid twits crooks. Cunning jim | spacedust | |
27/5/2020 08:45 | Yes EG Chart incoming | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions